ARCA in strategic review, evaluating additional development of assets, collaborations, other options

 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update.

In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor to explore and evaluate strategic options. The Board has not set a timetable for the conclusion of this review, nor has it made any decisions related to any further actions or potential strategic options at this time. There can be no assurance, however, that this process will result in any such transaction.

https://www.marketscreener.com/quote/stock/ARCA-BIOPHARMA-INC-56870636/news/ARCA-biopharma-Company-is-currently-engaged-in-a-strategic-review-process-evaluating-additional-d-43083870/